- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Checkpoint Inhibitors in Older Adults
Authors
Keywords
Immunotherapy, Checkpoint inhibitors, Anti-PD-1, Anti-CTLA-4, Older adults, Lung cancer, Melanoma, Renal cancer
Journal
Current Oncology Reports
Volume 18, Issue 8, Pages -
Publisher
Springer Nature
Online
2016-06-10
DOI
10.1007/s11912-016-0534-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 417OPhase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs):
- (2015) L. Horn et al. ANNALS OF ONCOLOGY
- 3094 Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC)
- (2015) S.N. Gettinger et al. EUROPEAN JOURNAL OF CANCER
- Defining a Role and Predicting Benefit From Platinum-Based Therapy in Breast Cancer: An Evolving Story
- (2015) Joseph A. Sparano JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural IgG Autoantibodies Are Abundant and Ubiquitous in Human Sera, and Their Number Is Influenced By Age, Gender, and Disease
- (2013) Eric P. Nagele et al. PLoS One
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunosenescence and cancer
- (2010) Graham Pawelec et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started